Tesaro Inc. (NASDAQ:TSRO)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $94.48 and last traded at $93.62, with a volume of 853,419 shares trading hands. The stock had previously closed at $93.38.

Several equities analysts recently weighed in on the company. Robert W. Baird assumed coverage on Tesaro in a research note on Monday, July 18th. They issued an “outperform” rating and a $105.00 price target for the company. Wells Fargo & Co. restated an “outperform” rating on shares of Tesaro in a research note on Thursday, June 30th. Wedbush restated a “buy” rating on shares of Tesaro in a research note on Thursday, June 30th. Mizuho restated an “outperform” rating and issued a $67.00 price target on shares of Tesaro in a research note on Thursday, June 30th. Finally, FBR & Co restated a “buy” rating on shares of Tesaro in a research note on Thursday, June 30th. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $76.50.

The stock’s 50 day moving average price is $69.58 and its 200-day moving average price is $48.71. The company’s market capitalization is $4.29 billion.

Tesaro (NASDAQ:TSRO) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.22) earnings per share for the quarter, missing the consensus estimate of ($1.69) by $0.53. During the same period last year, the business earned ($1.30) EPS. The firm had revenue of $0.31 million for the quarter, compared to analyst estimates of $2.48 million. Equities research analysts predict that Tesaro Inc. will post ($7.16) EPS for the current fiscal year.

In other news, VP Edward C. English sold 7,000 shares of the stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $40.75, for a total transaction of $285,250.00. Following the completion of the sale, the vice president now owns 3,500 shares in the company, valued at $142,625. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Jeffrey H. Hanke sold 12,500 shares of the stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $74.35, for a total transaction of $929,375.00. Following the sale, the vice president now owns 12,500 shares of the company’s stock, valued at approximately $929,375. The disclosure for this sale can be found here.

Other large investors have made changes to their positions in the company. Whittier Trust Co. increased its stake in shares of Tesaro by 1.1% in the fourth quarter. Whittier Trust Co. now owns 20,945 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 220 shares during the period. Rhumbline Advisers increased its stake in shares of Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 1,915 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock worth $1,275,000 after buying an additional 24,119 shares during the last quarter. Nationwide Fund Advisors increased its stake in shares of Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock worth $1,394,000 after buying an additional 330 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in shares of Tesaro during the fourth quarter worth approximately $1,864,000.

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.